Transparency

FAST (Foundation for Angelman Syndrome Therapeutics) is an Internal Revenue Code Section 501(c)(3), a nonprofit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members.

2016 – Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2016 Audited Financial Statements as well as a link to the FAST 2016 Federal Tax Return.  The FAST calendar year ended 2016 audited financials show total revenue of $4,475,739 and total expenses of $3,529,159. Expenses of $3,529,159 include research funding in the amount of $3,039,187 and $63,381 in other program-related expenses.  Fundraising expenses totaled $313,486, and general administrative expenses incurred by FAST in 2016 were $113,105.  $2,141,539 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2016 Audited Financials and Federal Tax Return.

2015 – Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2015 Audited Financial Statements as well as a link to the FAST 2015 Federal Tax Return.  The FAST calendar year ended 2015 audited financials show total revenue of $1,121,173 and total expenses of $1,348,143. Expenses of $1,348,143 include research funding in the amount of $1,116,067 and $125,910 in other program-related expenses.  Fundraising expenses totaled $82,549, and general administrative expenses incurred by FAST in 2015 were $23,617.  $1,194,959 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2015 Audited Financials and Federal Tax Return.

2014 – Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2014 Audited Financial Statement as well as a link to the FAST 2014 Federal Tax Return.  The FAST calendar year ended 2014 audited financials show total revenue of $1,576,826 and total expenses of $1,256,386. Expenses of $1,256,386 include research funding in the amount of $1,042,667 and $112,293 in other program-related expenses.  Fundraising expenses totaled $78,121, and general administrative expenses incurred by FAST in 2014 were $23,305.  $1,571,929 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST.  For detailed information, please see FAST 2014 Audited Financials and Federal Tax Return.

2013 – Below you will find a link to FAST (Foundation for Angelman Syndrome Therapeutics’) 2013 Audited Financial Statement as well as a link to the FAST 2013 Federal Tax Return. The FAST calendar year ended 2013 audited financials show total revenue of $913,798 and total expenses of $979,548. Expenses of $979,548 include research funding in the amount of $808,469 and $63,544 in other program-related expenses. Total general administrative expenses incurred by FAST in 2013 were $24,509. $1,101,489 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For detailed information, please see FAST 2013 Audited Financials and Federal Tax Return 2013.

2012 – The FAST calendar year ended 2012 audited financials show total revenue of $955,052 and total expenses of $391,600. Expenses of $391,600 include research funding in the amount of $253,890 and $58,550 in other program-related expenses.  Total general administrative expenses incurred by FAST in 2012 were $34,920, which included $17,476 of general administrative expenses and temporarily restricted funds of $17,444 for family travel expenses incurred in the Minocycline Clinical Trial.  $1,167,239 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2012 & Federal Tax Return 2012.

2011 – The FAST calendar year ended 2011 audited financials show total revenue of $639,525 and total expenses of $207,400. Expenses of $207,400 include research funding in the amount of $125,110 and other program-related expenses of $41,561.  Total general administrative expenses incurred by FAST in 2011 were $6,621.  $603,787 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2011 & Federal Tax Return 2011.

View our Conflict of Interest & Whistleblower Policy

^